East Bay drug maker to appeal FDA rejection of kidney treatment

Saying clinical trials show that its drug benefits kidney dialysis patients who suffer a potentially deadly buildup of a chemical in their blood, an East Bay company will appeal the Food and Drug Administration's rejection of the drug. Ardelyx Inc. (NASDAQ: ARDX) plans to submit a "formal dispute resolution request" to the FDA before the end of the year, the company said Thursday, appealing the FDA's decision not to approve the Fremont-based company's drug tenapanor. A decision could come within…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news